应用甲巯咪唑治疗初发甲状腺功能亢进致白细胞减少症的风险因素分析

Risk factors analysis of leukopenia in methimazole treatment of primary hyperthyroidism

目的探讨甲巯咪唑（MM）治疗初发甲状腺功能亢进（简称甲亢）致白细胞减少症的临床风险因素。方法收集100例给予MM治疗的初发甲亢患者的临床资料，对可能影响外周血白细胞减少的因素进行非条件Logistic回归分析。结果白细胞减少组与白细胞正常组性别比例、老年比例、过敏史、促甲状腺素受体抗体（TRAb）水平比较，差异无统计学意义（P〈0．05），Logistic多元回归分析结果显示，体质量指数（BMI）、MM起始剂量对回归方程有统计学意义（P〈0．05）。结论BMI、MM起始剂量是MM治疗初发甲亢最初3个月内发生白细胞减少症的危险因素。

Objective To explore the risk factors of leukopenia caused by methimazole treatment of primary hyperthyroidism. Methods 100 patients with hyperthyroidism in methimazole treatment were selected, affecting factors of leukopenia were analysed by means of multiple factors unconditional Logistic regression. Results Between patients with leukopenia and without leukopenia, there were no significant difference in sex ratio, the elderly proportion, drug allergy history and level of human thyroid stimulating hormone receptor antidoby（TRAb） （ P 〈 0.05 ） , multiple Logistic regression analysis results showed that body mass index （BMI） and the initial dose of methimazole had significant impact on the regression equation（ P 〈 O. 05 ）. Conclusion BMI and the initial dose of methimazole are the risk factors of leukopenia occurrence in methimazole treatment during the first three months.